About this trial
During the immune checkpoint inhibitor therapy (ICIT), most of the patients stay at home, but there is lacking of the studies to explore their physical and psychological distress, financial toxicity, care needs, and quality of life. Therefore, the aims of this program are to (1) explore the immune-related adverse event (irAE) severity, distress, financial toxicity, and quality of life and examine the psychometric testing of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM); (2) establish the LINE group for assessing irAE severity and change trajectory of quality of life in one-year follow-up and (3) combined retrospective chart review and the finding in aim (2) to develop the risk prediction model in order to identify the high risk population.
Eligibility criteria
Qualifiers
(1) Patients diagnose cancer and are informed
(2) Aged ≥18 years old
(3) Conscious clear and able to communicate
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Locations
1Sponsors and collaborators
Taipei Veterans General Hospital, Taiwan
Lead sponsor
National Yang Ming Chiao Tung University
Collaborator